Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 janv. 2026 10h02 HE | Source: Research and Markets

CD137 Targeted Therapy Research Report 2026-2030: 90 Therapies in Clinical Trials, Upcoming Commercial Launches, Global & Regional Clinical & Commercial Trends,

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026" report has been...
23 janv. 2026 05h52 HE | Source: Research and Markets

Oncolytic Virotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Oncolytic Virotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...
21 janv. 2026 11h12 HE | Source: Research and Markets

Photoimmunotherapy Market to Surge with 10.64% CAGR, Reaching USD 3.65 Billion by 2031

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Photoimmunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...
06 janv. 2026 09h13 HE | Source: Research and Markets

TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Report 2026-2030: Roche, Gilead Sciences, Merck, Arcus Biosciences, Compugen, and Vir Biotechnology Advance Deep Oncology Pipelines

Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. ...
27 nov. 2025 09h02 HE | Source: Research and Markets

PD-L1 X 4-1BB (CD137) Bispecific Antibodies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of PD-L1 x 4-1BB (CD137) Bispecific Antibodies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence...
27 nov. 2025 08h58 HE | Source: Research and Markets

CD40 Agonists and CD40/L Antagonists Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD40 Agonists and CD40/L Antagonists" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
27 nov. 2025 08h47 HE | Source: Research and Markets

CD73 Inhibitors Pipeline Report 2025: an Up-to-date Competitor Evaluation in the Field of Antibodies, RNA and Small Molecules in Research and Development Inhibiting CD73

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD73 Inhibitors" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about CD73 Inhibitors...
27 nov. 2025 08h17 HE | Source: Research and Markets

C-Met-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of c-Met-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
25 nov. 2025 10h01 HE | Source: Research and Markets

PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff

Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
07 nov. 2025 09h00 HE | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

New translational data supports potential of NX-1607 as a novel next generation checkpoint inhibitor therapy

Page suivante